The Intrauterine Device: How to Deploy This Strategy in the Molecular World?

Advanced Search

Paul Johannet, Claire F Friedman

Author Information

Paul Johannet: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ORCID
Claire F Friedman: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. ORCID

PMID: 39254401 DOI: 10.1158/1078-0432.CCR-24-2034

Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine device confers durable clinical benefit and identifies possible immune mechanisms of relapse and resistance. See related article by Bowen et al., p. 5073.

Clin Cancer Res. 2006 Nov 1;12(21):6373-8 [PMID: 17085648]
Hum Reprod. 2004 Apr;19(4):815-21 [PMID: 15033949]
Clin Cancer Res. 2024 Nov 15;30(22):5073-5082 [PMID: 38922360]
J Exp Med. 2002 Aug 19;196(4):459-68 [PMID: 12186838]
Gynecol Oncol. 2023 Jul;174:262-272 [PMID: 37245486]
Gynecol Oncol. 2023 Dec;179:180-187 [PMID: 37992549]

P30 CA008748/NCI NIH HHS

Humans

Female

Endometrial Neoplasms

Fertility Preservation

Intrauterine Devices

Levonorgestrel

Endometrial Hyperplasia

Progestins

Intrauterine Devices, Medicated

Levonorgestrel

Progestins

Journal Article

No available data.

OpenLB
Open Library of Bioscience